Kimimasa Nakabayashi , Yasunori Fujioka ,Yoshihiro Arimura ,Toshihito Fukuoka ,Tomofumi Marumo ,Michiru Umino ,Yasushi Kamiya ,Takahiro Okai ,Shigeru Tsurumaki ,Toshihiko Nagasawa ,Akira Yamada	Anti-glomerular basement membrane (anti-GBM) disease accompanied by vasculitis that was not positive for antineutrophil cytoplasmic antibodies to myeloperoxidase and proteinase 3: a report of two cases and the incidence of anti-GBM disease at one institution.	Clin Exp Nephrol.	15	504-513	2011
Arimura Y(分担執筆)	Guideline for Management of Vasculitis Syndrome(JCS2008)JCS Joint Working Group.	Circulation Journal.	75(2)	474-503	2011
Kurata A, Arimura Y, Iwasawa A, Kawashima S, Ikegaya N, Kojima K, Fujioka Y, Nakabayashi K, Yamada A	Identification of MPO-positive capillaries of the pleura by immunohistochemistry in MPO-ANCA associated vasculitis.	Pathol Int.	60(9)	626-9	2011
有村義宏	3. 内科医が知っておくべき腎臓と全身臓器とのインターラクション 1) 肺と腎臓	日本内科学会雑誌	100 (9)	2530-2536	2011
有村義宏	ANCA 関連血管炎に伴う尿細管間質性腎炎	日本腎臓学会誌	53 (4)	604-609	2011
駒形嘉紀,有村義宏	結節性多発動脈炎	リウマチ科	45 (4)	371-378	2011
山村昌弘,佐田憲映,針谷正祥,藤井隆夫,有村義宏,槇野 博史	Remit－JAV 研究：わが国の ANCA 関連血管炎の診察実態の把握を目指して	脈管学	51 (1)	79-85	2011
有村義宏	壊死性糸球体腎炎	別冊 日本臨床 新領域別症候群シリーズ	No. 17	65-69	2012
Yamagata K, Usui J, Saito C, Yamaguchi N, Hirayama K, Mase K, Kobayashi M, Koyama A, Sugiyama H, Nitta K, Wada T, Muso E, Arimura Y, Makino H, Matsuo S.	ANCA-associated systemic vasculitis in Japan: clinical features and prognostic changes.	Clin Exp Nephrol	16	580-588	2012

有村義宏	顕微鏡的多発血管炎	日本医師会雑誌	140(11)	2305-2309	2012
有村義宏	壊死性糸球体腎炎．腎臓症候群（第2版）—その他の腎臓疾患を含めて—．	別冊　日本臨床　新領域別症候群シリーズ	17	65-69	2012
有村義宏	ANCA関連腎炎．腎臓症候群（第2版）—その他の腎臓疾患を含めて—	別冊　日本臨床　新領域別症候群シリーズ	18	468-473	2012
Wada T, Hara A, Arimura Y, Sada K, Makino H, and the Research Group of Intractable Vasculitis, Ministry of Health, Labor, and Welfare of Japan.	Risk Factors Associated with Relapse in Japanese Patients with Microscopic Polyangiitis.	The Journal of Rheumatology	39(3)	545-551	2012
有村義宏	ANCA関連血管炎の成因．特集：免疫異常と腎障害 ANCA関連血管炎の成因．	腎臓	35(1)	32-38	2012
有村義宏	ANCA関連血管炎に伴う糸球体病変—Glomerular lesion in ANCA-associated vasculitis—．治療各論　続発性腎疾患	腎と透析	72 増刊号	286-290	2012
有村義宏,吉澤亮,清水英樹	血管炎研究の進歩-側頭動脈炎,多発性動脈炎-.	心臓	44(9)	1110-1115	2012
有村義宏	KDIGO:糸球体腎炎診療ガイドライン	腎と透析	73(4)	591-594	2012
Komagata.Y, Nomura K, Yoshihara K, Kawashima S, Kaname S, Arimura Y, Yamada A	AP-VAS2012 case report: MPO-ANCA-negative relapse of MPO-ANCA-associated vasculitis.	CEN Case Reports.	2	180-183	2013
有村義宏	血管炎の最新知見.	第110回日本内科学会講演会 教育講演日本内科学会雑誌.	102(9)	2382-2390	2013
Arimura Y, Kawashima S,Yoshihara K,Komagata Y,Kaname S,Yamada A	The role of myeloperoxidase and myeloperoxidase-antineutrophil cytoplasmic antibodies(MPO-ANCAs) in the pathogenesis of human MPO-ANCA-associated glomerulonephritis.	Clin Exp Nephrol.	17	634-637	2013

Kawashima S, Arimura Y, Sano K, Kudo A, Komagata Y, Kaname S, Kawakami H, Yamada A	Immunopathologic co-localization of MPO, IgG, and C3 in glomeruli in human MPO-ANCA-associated glomerulonephritis.	Clin Nephrol.	79(4)	292-301	2013
松田朝子、有村義宏、吉原　堅、駒形嘉紀、要　伸也、山田　明	好酸球性多発血管炎性肉芽腫症（Churg-Strauss 症候群）寛解期の末梢神経障害に対する大量γグロブリン療法の有効性.	日本臨床免疫学会会誌	36(4)	217-225	2013
有村義宏	ANCA 関連血管炎（顕微鏡的多発血管炎，多発血管炎性肉芽腫症，好酸球性多発血管炎性肉芽腫症）.	腎と透析	74 増刊号	196-198	2013
有村義宏	顕微鏡的多発血管炎の予後.	リウマチ科	49(6)	673-678	2013
有村義宏	顕微鏡的多発血管炎.	医学のあゆみ	246(1)	37-43	2013
Yamagata K, Usui J, Sugiyama H, Nitta K, Wada T, Muso E, Arimura Y, Koyama A, Makino H, Matsuo S	Clinical finding on ANCA-associated renal vasculitis from the Japan RPGN registry obtained via a quesitionnaire survey.	Clin Exp Nephrol	17	646-649	2013
Minako Wakasugi, Junichiro James Kazama, Masatomo Taniguchi, Atsushi Wada, Kunitoshi Iseki, Yoshiharu Tsubakihara, Ichiei Narita	Increased risk of hip fracture among Japanese hemodialysis patients.	J Bone Miner Metab	31	315-321	2013
Takayoshi Miura, Shin Goto, Seitaro Iguchi, Mitsuhiro Ueno, Shin-ici Nishi, Ichiei Narita	Membranoproliferative pattern of glomerular injury associated with complement component 9 deficiency due to Arg95Stop mutation.	Clinical and Experimental Nephrology	15(1)	86-91	2011
Wang-Rosenke Y, Khadzhynov D, Loof T, Mika A, Kawachi H, Neumayer HH, Peters H.	Tyrosine kinases inhibition by Imatinib slows progression in chronic anti-thy1 glomerulosclerosis of the rat.	BMC Nephrol.	14	223-35	2013
Babayeva S, Rocque B, Aoudjit L, Zilber Y, Li J, Baldwin C, Kawachi H, Takano T, Torban E.	Planar cell polarity pathway regulates nephrin endocytosis in developing podocytes.	J Biol Chem	288(33)	24035-48	2013

Soetikno V, Sari FR, Lakshmanan AP, Arumugam S, Harima M, Suzuki K, Kawachi H, Watanabe K.	Curcumin alleviates oxidative stress, inflammation, and renal fibrosis in remnant kidney through the Nrf2-keap1 pathway.	Mol Nutr Food Res.	57(9)	1649-59	2013
Lakshmanan AP, Harima M, Suzuki K, Soetikno V, Nagata M, Nakamura T, Takahashi T, Sone H, Kawachi H, Watanabe K.rotein response (UPR) signaling proteins.	The hyperglycemia stimulated myocardial endoplasmic reticulum (ER) stress contributes to diabetic cardiomyopathy in the transgenic non-obese type 2 diabetic rats: a differential role of unfolded protein response (UPR) signaling proteins.	Int J Biochem Cell Biol.	45(2)	438-47	2013
Soetikno V, Sari FR, Sukumaran V, Lakshmanan AP, Harima M, Suzuki K, Kawachi H, Watanabe K.	Curcumin decreases renal triglyceride accumulation through AMPK-SREBP signaling pathway in streptozotocin-induced type 1 diabetic rats.	J Nutr Biochem	24(5)	796-802	2013
Yamaguchi H, Suzuki K, Nagata M, Kawase T, Sukumaran V, Thandavarayan RA, Kawauchi Y, Yokoyama J, Tomita M, Kawachi H, Watanabe K, Yoneyama H, Asakura H, Takagi R.	Irsogladine maleate ameliorates inflammation and fibrosis in mice with chronic colitis induced by dextran sulfate sodium.	Med Mol Morphol.	45(3)	140-51	2012
Tanabe M, Shimizu A, Masuda Y, Kataoka M, Ishikawa A, Wakamatsu K, Mii A, Fujita E, Higo S, Kaneko T, Kawachi H, Fukuda Y.	Development of lymphatic vasculature and morphological characterization in rat kidney.	Clin Exp Nephrol.	16(6)	833-42	2012
Sato A, Piao H, Nozawa Y, Morioka T, Kawachi H, Oite T.	Local delivery of a direct renin inhibitor into the kidney ameliorates progression of experimental glomerulonephritis.	Clin Exp Nephrol.	16(4)	539-48	2012

Sofue T, Kiyomoto H, Kobori H, Urushihara M, Nishijima Y, Kaifu K, Hara T, Matsumoto S, Ichimura A, Ohsaki H, Hitomi H, Kawachi H, Hayden MR, Whaley-Connell A, Sowers JR, Ito S, Kohno M, Nishiyama A.	Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.	Am J Hypertens.	25(5)	604-11	2012
Toyama K, Morisaki H, Cheng J, Kawachi H, Shimizu F, Ikawa M, Okabe M, Morisaki T.	Proteinuria in AMPD2-deficient mice.	Genes Cells.	17(1)	28-38	2012
Ramadan R, Faour D, Awad H, Khateeb E, Cohen R, Yahia A, Torgovicky R, Cohen R, Lazari D, Kawachi H, Abassi Z.	Early treatment with everolimus exerts nephroprotective effect in rats with adriamycin-induced nephrotic syndrome.	Nephrol Dial Transplant.	27(6)	2231-41	2012
Kinoshita Y, Kondo S, Urushihara M, Suga K, Matsuura S, Takamatsu M, Shimizu M, Nishiyama A, Kawachi H, Kagami S.	Angiotensin II type I receptor blockade suppresses glomerular renin-angiotensin system activation, oxidative stress, and progressive glomerular injury in rat anti-glomerular basement membrane glomerulonephritis.	Transl Res.	158(4)	235-48	2011
Soetikno V, Sari FR, Veeraveedu PT, Thandavarayan RA, Harima M, Sukumaran V, Lakshmanan AP, Suzuki K, Kawachi H, Watanabe K	Curcumin ameliorates macrophage infiltration by inhibiting NF-κB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy.	Nutr Metab (Lond).	8(1)	35-46	2011

Suzuki K, Sun X, Nagata M, Kawase T, Yamaguchi H, Sukumaran V, Kawauchi Y, Kawachi H, Nishino T, Watanabe K, Yoneyama H, Asakura H.	Analysis of intestinal fibrosis in chronic colitis in mice induced by dextran sulfate sodium.	Pathol Int.	61(4)	228-38	2011
Ikezumi Y, Suzuki T, Karasawa T, Hasegawa H, Yamada T, Imai N, Narita I, Kawachi H, Polkinghorne KR, Nikolic-Paterson DJ, Uchiyama M.	Identification of alternatively activated macrophages in new-onset paediatric and adult immunoglobulin A nephropathy: potential role in mesangial matrix expansion.	Histopathology.	58(2)	198-210	2011
Miyasato K, Takabatake Y, Kaimori J, Kimura T, Kitamura H, Kawachi H, Li XK, Hünig T, Takahara S, Rakugi H, Isaka Y.	CD28 superagonist-induced regulatory T cell expansion ameliorates mesangioproliferative glomerulonephritis in rats.	Clin Exp Nephrol.	15(1)	18445	2011
Saito A, Miyauchi N, Hashimoto T, Karasawa T, Han GD, Kayaba M, Sumi T, Tomita M, Ikezumi Y, Suzuki K, Koitabashi Y, Shimizu F, Kawachi H.	Neurexin-1, a presynaptic adhesion molecule, localizes at the slit diaphragm of the glomerular podocytes in kidneys.	Am J Physiol Regul Integr Comp Physiol.	300(2)	R340-8	2011
Kojima K, Nosaka H, Kishimoto Y, Nishiyama Y, Fukuda S, Shimada M, Kodaka K, Saito F, Matsumura K, Shimizu T, Toda T, Takeda S, Kawachi H, Uchida S.	Defective glycosylation of α-dystroglycan contributes to podocyte flattening.	Kidney Int.	79(3)	311-6	2011
河内裕、高橋彩、山﨑美穂子、福住好恭、富田雅之	腎糸球体上皮細胞（ポドサイト）スリット膜の構造と機能－ARB のポドサイト保護作用－	Pharma Medica	31(5)	36039	2013
河内裕、長田道夫	膜性腎症（特発性膜性腎症）	腎臓	33	227-31	2011
長田道夫、河内裕	ループス腎炎モデル	腎臓	34	48-53,	2011

前嶋明人	ワンポイントアドバイス「蛋白尿・血尿-腎臓専門医に紹介するタイミング-」	Medical Practice	30巻6号	1098		2013
前嶋明人、野島美久	早期診断と治療「全身性エリテマトーデス」	内科	112巻1号	33-37		2013
前嶋明人	実地医家のための臨床検査のすすめかた・評価のしかた「腎・泌尿器疾患 I. 症候から診断へ」	Medical Practice	2012年臨時増刊号	78-84		2012
前嶋明人、野島美久	ループス腎炎の治療と予後	リウマチ科	47巻5号	481-487		2012
前嶋明人、野島美久	各種病態にみられる腎障害「血栓性血小板減少性紫斑病」	日本臨床	新領域別症候群シリーズNo.18 腎臓症候群(第2版)	405-408		2012
松本　啓、横尾隆	腎臓の幹細胞を用いた三次元的再生	腎と透析	75	839-843		2013
横尾　隆	臨床応用に向けた腎臓再生研究	日本透析医学会雑誌	46	1055-1060		2013
福井　亮、横尾隆	腎臓と再生医療　特集；腎臓学この一年の進歩	日本腎臓学会誌	56	8-13		2014
Yokote S, Yokoo T	Organogenesis for kidney regeneration	Curr Opin Organ Transplant	18	186-190		2013
Araoka T, Mae S, Kurose Y, Uesugi M, Ohta A, Yamanaka S, Osafune K.	Efficient and rapid induction of human iPSCs/ESCs into nephrogenic intermediate mesoderm using small molecule-based differentiation methods.	PLoS One	9	e84881		2014
Mae S, Shono A, Shiota F, Yasuno T, Kajiwara M, Gotoda-Nishimura N, Arai S, Sato-Otubo A, Toyoda T, Takahashi K, Nakayama N, Cowan CA, Aoi T, Ogawa S, McMahon AP, Yamanaka S, Osafune K.	Monitoring and robust induction of nephrogenic intermediate mesoderm from human pluripotent stem cells.	Nature Communications	4	1367		2013
笠原 朋子、前 伸一、長船 健二	iPS細胞を用いた腎臓再生研究の進展	医学のあゆみ	248	157-158		2014
豊原 敬文、長船健二	iPS細胞を用いた腎疾患治療	腎と透析	75	850-853		2013
長船 健二	iPS細胞を用いた腎臓再生と新規腎疾患モデルの作製	日本小児腎臓病学会雑誌	26	64-69		2013

丸山彰一、秋山真一、松尾清一	慢性腎症とPLA2R1 抗体	腎と透析	76（1）	13-148	2014
丸山彰一	Ⅰ.診断法　4.ネフローゼ症候群	日本内科学会雑誌	102（5）	1098-1104	2013
松尾清一	腎臓病における疾患概念と臨床研究	日本内科学会雑誌	102（5）	1067-1069	2013

SPECIAL REPORT

Japan Renal Biopsy Registry and Japan Kidney Disease Registry: Committee Report for 2009 and 2010

Hitoshi Sugiyama · Hitoshi Yokoyama · Hiroshi Sato · Takao Saito · Yukimasa Kohda · Shinichi Nishi ·
Kazuhiko Tsuruya · Hideyasu Kiyomoto · Hiroyuki Iida · Tamaki Sasaki · Makoto Higuchi ·
Motoshi Hattori · Kazumasa Oka · Shoji Kagami · Tetsuya Kawamura · Tetsuro Takeda · Hiroshi Hataya ·
Yuichiro Fukasawa · Atsushi Fukatsu · Kunio Morozumi · Norishige Yoshikawa · Akira Shimizu ·
Hiroshi Kitamura · Yukio Yuzawa · Seiichi Matsuo · Yutaka Kiyohara · Kensuke Joh · Michio Nagata ·
Takashi Taguchi · Hirofumi Makino · Committee for Standardization of Renal Pathological Diagnosis
and Committee for Kidney Disease Registry, Japanese Society of Nephrology, Japan

Abstract The Japan Renal Biopsy Registry (J-RBR) was started in 2007 and the Japan Kidney Disease Registry (J-KDR) was then started in 2009 by the Committee for Standardization of Renal Pathological Diagnosis and the Committee for the Kidney Disease Registry of the Japanese Society of Nephrology. The purpose of this report is to describe and summarize the registered data from 2009 and 2010. For the J-KDR, data were collected from 4,016 cases, including 3,336 (83.1 %) by the J-RBR and 680 (16.9 %) other cases from 59 centers in 2009, and from 4,681 cases including 4,106 J-RBR cases (87.7 %) and 575 other cases (12.3 %) from 94 centers in 2010, including the affiliate hospitals. In the J-RBR, 3,165 native kidneys (94.9 %) and 171 renal grafts (5.1 %) and 3,869 native kidneys (94.2 %) and 237 renal grafts (5.8 %) were registered in 2009 and 2010, respectively. Patients younger than 20 years of age comprised 12.1 % of the registered cases, and those 65 years and over comprised 24.5 % of the cases with native kidneys in 2009 and 2010. The most common clinical diagnosis was chronic

H. Sugiyama · H. Makino
Department of Medicine and Clinical Science, Okayama
University Graduate School of Medicine, Dentistry, and
Pharmaceutical Sciences, Okayama, Japan

H. Yokoyama (✉)
Division of Nephrology, Kanazawa Medical University School
of Medicine, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan
e-mail: h-yoko@kanazawa-med.ac.jp

H. Sato
Division of Nephrology, Tohoku University Graduate School
of Medicine, Sendai, Japan

T. Saito
Division of Nephrology and Rheumatology, Department
of Internal Medicine, Fukuoka University School of Medicine,
Fukuoka, Japan

Y. Kohda
Department of Nephrology, Faculty of Life Sciences,
Kumamoto University, Kumamoto, Japan

Present Address:
Y. Kohda
Hikarinomori Clinic, Kumamoto, Japan

S. Nishi
Division of Nephrology and Kidney Center, Kobe University
School of Medicine, Kobe, Japan

K. Tsuruya
Department of Integrated Therapy for Chronic Kidney Disease,
Graduate School of Medical Sciences, Kyushu University,
Fukuoka, Japan

H. Kiyomoto
Division of Integrated Nephrology and Telemedicine,
Department of Community Medical Supports, Tohoku Medical
Megabank Organization, Tohoku University, Sendai, Japan

H. Iida
Department of Internal Medicine, Toyama Prefectural Central
Hospital, Toyama, Japan

T. Sasaki
Division of Nephrology and Hypertension, Department
of Internal Medicine, Kawasaki Medical School, Kurashiki,
Japan

M. Higuchi
Division of Nephrology, Department of Internal Medicine,
Shinshu University School of Medicine, Matsumoto, Japan

🦊 Springer

nephritic syndrome (55.4 % and 50.0 % in 2009 and 2010, respectively), followed by nephrotic syndrome (22.4 % and 27.0 %); the most frequent pathological diagnosis as classified by the pathogenesis was IgA nephropathy (31.6 % and 30.4 %), followed by primary glomerular diseases (except IgA nephropathy) (27.2 % and 28.1 %). Among the primary glomerular diseases (except IgA nephropathy) in the patients with nephrotic syndrome, membranous nephropathy was the most common histopathology in 2009 (40.3 %) and minor glomerular abnormalities (50.0 %) were the most common in 2010 in native kidneys in the J-RBR. Five new secondary and longitudinal research studies by the J-KDR were started in 2009 and one was started in 2010.

Introduction

The Japanese Society of Nephrology (JSN) established the Japan Renal Biopsy Registry (J-RBR) in 2007, and it conducted analyses for 2007 and 2008 [1]. In 2009, the JSN started the Japan Kidney Disease Registry (J-KDR) to record clinically-diagnosed cases in addition to the J-RBR. Participation in the J-KDR, including the J-RBR, was

requested from appointed clinical training hospitals of the JSN and the Japanese Society for Dialysis Therapy in an attempt to extend the registry nationwide. In this report, the detailed data of the J-RBR and the frequencies of the different clinical diagnoses in the J-KDR registered from January to December of 2009 and 2010 are summarized.

Subjects and methods

Registry system and patients

This report includes the data from patients included in the J-RBR and J-KDR (J-RBR/J-KDR), registered prospectively from January 2009 to December 2010. The patients' data, including age, gender, laboratory data, and the clinical and pathological diagnoses, were recorded at each institution and registered on the web page of the J-RBR/J-KDR utilizing the Internet Data and Information Center for Medical Research (INDICE) system of the University Hospital Medical Information Network (UMIN), as described previously [1]. The ethics committee of the JSN and that of Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences comprehensively approved the study, and a local committee of participating centers and their affiliate hospitals individually approved the study. Written informed consent was

M. Hattori
Department of Pediatric Nephrology, Tokyo Women's Medical University, School of Medicine, Tokyo, Japan

K. Oka
Department of Pathology, Hyogo Prefectural Nishinomiya Hospital, Hyogo, Japan

S. Kagami
Department of Pediatrics, The Institute of Health Bioscience, The University of Tokushima Graduate School, Tokushima, Japan

T. Kawamura
Department of Medicine, Division of Kidney and Hypertension, Jikei University School of Medicine, Tokyo, Japan

T. Takeda
Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

Present Address:
T. Takeda
Department of Nephrology, Dokkyo Medical University Koshigaya Hospital, Koshigaya, Japan

H. Hataya
Department of Nephrology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan

Y. Fukasawa
Department of Pathology, KKR Sapporo Medical Center, Sapporo, Japan

A. Fukatsu
Department of Nephrology, Kyoto University Graduate School of Medicine, Kyoto, Japan

Present Address:
A. Fukatsu
Department of Nephrology, Yachiyo Hospital, Anjo, Japan

K. Morozumi
Kidney Center, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan

N. Yoshikawa
Department of Pediatrics, Wakayama Medical University, School of Medicine, Wakayama, Japan

A. Shimizu
Department of Pathology, Nippon Medical School, Tokyo, Japan

H. Kitamura
Department of Pathology, Clinical Research Center, National Hospital Organization Chiba East National Hospital, Chiba, Japan

obtained from the patients at the time of biopsy or at the time they were registered to participate in the study. The J-RBR/J-KDR is registered in the Clinical Trial Registry of UMIN (Registered Number UMIN000000618).

Clinical or renal histopathological diagnosis and laboratory data

Three classifications, including the clinical diagnosis, histological diagnosis based on the pathogenesis, and histological diagnosis based on a histopathological examination, were made for each case included in the J-RBR, as described previously [1]. Of these classifications, the clinical diagnosis alone was selected for the J-KDR. The definition of each diagnosis was based on the clinical syndromes and renal histopathology, as described previously [2]. IgA nephropathy (IgAN) (Berger disease) was separated from primary glomerular diseases on the basis of basic glomerular alterations in the classification of glomerular diseases by the World Health Organization [2]. In 2010, hemolytic uremic syndrome and thrombotic thrombocytopenic purpura (HUS/TTP), congenital anomalies of the kidney and urinary tract (CAKUT) and polycystic kidney disease (PKD) were added to the classification of the clinical diagnosis on the case record (Table S1). The clinical data, including the results of the urinalysis, daily proteinuria, serum creatinine concentrations, total protein,

Y. Yuzawa
Department of Nephrology, Fujita Health University School of Medicine, Toyoake, Japan

S. Matsuo
Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Y. Kiyohara
Department of Environmental Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

K. Joh
Division of Pathology, Sendai Shakai Hoken Hospital, Sendai, Japan

M. Nagata
Molecular Pathology, Biomolecular and Integrated Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan

T. Taguchi
Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan

Present Address:
T. Taguchi (✉)
Department of Pathology, Nagasaki Municipal Hospital, Nagasaki, Japan
e-mail: taguchi@nagasaki-u.ac.jp

albumin, and the total cholesterol values, were always recorded, while the systolic and diastolic blood pressure, prescription use of anti-hypertensive agents, hemoglobin A1c, and presence of diabetes mellitus were optionally recorded. The estimated glomerular filtration rate was calculated as described previously [3]. The frequency of the diseases are here described in general, but the clinical data were also analyzed separately for cases of IgAN, which is the most common renal disease in Japan [1, 4, 5].

Statistical analyses

Data are expressed as the mean ± SD for continuous parametric data, medians and interquartile ranges for continuous non-parametric data, and frequencies for categorical data. The statistical analyses were performed using the JMP software program, version 8 (SAS Institute Inc., Cary, NC, USA).

Results

Baseline characteristics of the J-RBR/J-KDR participants in 2009 and 2010

The numbers of participating facilities and registered renal biopsies or cases without renal biopsies in the registry in 2009 and 2010 are shown in Table 1. The J-KDR was started in 2009 and the number of participating facilities increased by 34 compared to 2008, reaching a total of 57 facilities in the J-RBR and 59 facilities in the J-KDR. The number of total renal biopsies increased to 3,336 in 2009, which was 1,754 more biopsies than in the previous year [1], and in 2010 it further increased to 4,106 in the J-RBR. The number of other cases (not in the J-RBR), which corresponds to the cases without renal biopsies but diagnosed by clinical findings, was 680 and 575 in 2009 and 2010, respectively. The average age of this cohort was more than 10 years higher than that of the J-RBR in each year (Table 1).

The number of native kidney biopsies increased; however, that of renal graft biopsies registered in 2009 slightly decreased compared to 2008 (Table 2). The distribution of age ranges showed a peak distribution in the seventh decade in both genders for native kidneys (Table 3). Patients younger than 20 years of age comprised 12.1 % and 10.3 % of the cases, and those 65 years of age and over comprised 24.5 % and 4.7 % of the native kidney and renal grafts, respectively, during the 2-year period (2009 and 2010). In the patients who underwent renal grafts, both the average age and the peak distribution of age ranges were younger than those of patients who underwent native kidney biopsies (Tables 2, 3).

Table 1 The number of participated renal centers and registered renal biopsies or other cases without renal biopsies in J-RBR/J-KDR 2009 and 2010

	2009 J-KDR			2010 J-KDR		
	J-RBR	Other cases[a]	Total	J-RBR	Other cases[a]	Total
Renal centers (n)[b]	57[c]	–	59	83	–	94
Total biopsies or cases (n)	3,336[d] (83.1 %)	680 (16.9 %)	4,016 (100.0 %)	4,106 (87.7 %)	575 (12.3 %)	4,681 (100.0 %)
Average age (years)	46.7 ± 19.9	58.1 ± 17.8	48.7 ± 20.0	46.7 ± 20.6	56.8 ± 21.1	47.9 ± 20.9
Male (n)	1,787 (53.6 %)	418 (61.5 %)	2,205 (54.9 %)	2,183 (53.2 %)	335[e] (58.3 %)	2,518[e] (53.8 %)
Female (n)	1,549 (46.4 %)	262 (38.5 %)	1,811 (45.1 %)	1,923 (46.8 %)	238[e] (41.4 %)	2,161[e] (46.2 %)

J-RBR Japan Renal Biopsy Registry, *J-KDR* Japan Kidney Disease Registry

Note that J-RBR started in 2007 and J-KDR started in 2009

[a] Other cases include patients diagnosed by clinical findings without renal biopsies

[b] The number represents principal institutions having affiliate hospitals. All of the participated institutions and hospitals in the J-RBR and J-KDR in 2009 and 2010 are shown in the "Appendix". The number of renal centers in total is based on the registration of cases without renal biopsies but diagnosed by clinical findings in addition to that of data with renal biopsy in J-RBR

[c] Increase of 34 when compared to the number in J-RBR 2008

[d] Increase of 1,754 when compared to the number in J-RBR 2008

[e] No registered data for gender in 2 cases

The frequency of clinical diagnoses in the J-RBR

Three classifications, the clinical diagnosis, histological diagnosis based on the pathogenesis, and the histological diagnosis based on a histopathological examination, were included in the J-RBR database, while the clinical diagnosis alone was registered for the other cases. In the J-RBR, a clinical diagnosis of chronic nephritic syndrome was the most common, followed by nephrotic syndrome, in both total biopsies and native kidneys in 2009 and 2010, which was similar to the findings in 2007 and 2008 (Table 4) [1]. In native kidneys, more than half of the cases that were registered had chronic nephritic syndrome. The age distribution according to the classification of clinical diagnoses in native kidneys in the J-RBR in 2009 and 2010 was analyzed, and cases with rapidly progressive nephritic syndrome exhibited the highest mean age while cases with inherited renal diseases showed the youngest mean age (Table 5).

The frequency of pathological diagnoses in the J-RBR

The pathological diagnoses were classified based on the pathogenesis (Table 6) and histopathology (Table 7). In the classification of the pathogenesis, IgAN was diagnosed most frequently (31.6 %), followed by primary glomerular disease other than IgAN (27.2 %) in native kidneys in both 2009 and 2010 (Table 6). Similar frequencies of IgAN, primary glomerular disease other than IgAN and diabetic nephropathy were observed in the combined data for 2007 and 2008 [1]. In the pathological diagnosis classified based on the histopathology in native kidney biopsies, mesangial

Table 2 The number of registered renal biopsies in J-RBR 2009 and 2010

Years	2009	2010	Total
Native kidneys, n (%)	3,165[a] (94.9)	3,869 (94.2)	7,034 (94.5)
Average age (years)	47.0 ± 20.1	47.1 ± 20.8	47.1 ± 20.5
Median age (years)	50 (30–64)	49 (31–65)	49 (30–64)
Male, n (%)	1,671 (52.8)	2,035 (52.6)	3,706 (52.7)
Female, n (%)	1,494 (47.2)	1,834 (47.4)	3,328 (47.3)
Renal grafts, n (%)	171[b] (5.1)	237 (5.8)	408 (5.5)
Average age (years)	40.9 ± 15.0	41.3 ± 15.4	41.1 ± 15.2
Median age (years)	43 (31–52)	41 (33–54)	42 (32–53)
Male, n (%)	116 (67.8)	148 (62.4)	264 (64.7)
Female, n (%)	55 (32.2)	89 (37.6)	144 (35.3)

[a] Increase of 1,765 when compared to the number in J-RBR 2008

[b] Decrease of 11 when compared to the number in J-RBR 2008

proliferative glomerulonephritis was the most frequently observed disease, representing 42.5 % and 35.8 % of the cases in 2009 and 2010 (Table 7).

Primary glomerular disease (except IgAN) and nephrotic syndrome in the J-RBR

In the cohort of primary glomerular diseases (except IgA nephropathy) as classified based on the pathogenesis, membranous nephropathy (MN) was predominant in 2009, followed by minor glomerular abnormalities, while minor glomerular abnormalities were the most common diagnosis in 2010, followed by MN (Table 8).

Table 3 Distribution of age ranges and gender in J-RBR 2009 and 2010

Age (years)	2009									2010								
	Total biopsies ($n = 3,336$)			Native kidneys ($n = 3,165$)			Renal grafts ($n = 171$)			Total biopsies ($n = 4,106$)			Native kidneys ($n = 3,869$)			Renal grafts ($n = 237$)		
	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female
0–9	60	33	27	57	32	25	3	1	2	121	94	27	136	87	49	7	7	0
10–19	318	169	149	304	160	144	14	9	5	352	203	149	354	193	161	18	10	8
20–29	413	194	219	392	180	212	21	14	7	406	187	219	429	167	262	22	20	2
30–39	476	221	255	438	193	245	38	28	10	533	278	255	549	248	301	62	30	32
40–49	434	222	212	391	197	194	43	25	18	489	277	212	489	251	238	50	26	24
50–59	545	317	228	509	291	218	36	26	10	575	347	228	541	311	230	49	36	13
60–69	645	382	263	631	371	260	14	11	3	733	470	263	756	452	304	28	18	10
70–79	372	213	159	370	211	159	2	2	0	437	278	159	515	277	238	1	1	0
80+	73	36	37	73	36	37	0	0	0	86	49	37	100	49	51	0	0	0
Total	3,336	1,787	1,549	3,165	1,671	1,494	171	116	55	3,732	2,183	1,549	3,869	2,035	1,834	237	148	89
Under 20 (%)	11.3	11.3	11.4	11.4	11.5	11.3	9.9	8.6	12.7	12.5	13.6	11.4	12.7	13.8	11.5	10.5	11.5	9.0
65 and over (%)	22.4	23.9	20.1	23.4	25.3	21.3	4.7	4.3	5.5	24.2	25.4	20.7	25.4	26.9	23.7	4.6	5.4	3.4

Age (years)	Total								
	Total biopsies ($n = 7,442$)			Native kidneys ($n = 7,034$)			Renal grafts ($n = 408$)		
	Total	Male	Female	Total	Male	Female	Total	Male	Female
0–9	203	127	76	193	119	74	10	8	2
10–19	690	372	318	658	353	305	32	19	13
20–29	864	381	483	821	347	474	43	34	9
30–39	1,087	499	588	987	441	546	100	58	42
40–49	973	499	474	880	448	432	93	51	42
50–59	1,135	664	471	1,050	602	448	85	62	23
60–69	1,429	852	577	1,387	823	564	42	29	13
70–79	888	491	397	885	488	397	3	3	0
80+	173	85	88	173	85	88	0	0	0
Total	7,442	3,970	3,472	7,034	3,706	3,328	408	264	144
Under 20 (%)	12.0	12.6	11.3	12.1	12.7	11.4	10.3	10.2	10.4
65 and over (%)	23.4	24.7	21.8	24.5	26.1	22.6	4.7	4.9	4.2

Table 4 The frequency of classification of clinical diagnoses in J-RBR 2009 and 2010

Classification	2009			2010			Total		
	Total biopsies ($n = 3,336$)		Native kidneys ($n = 3,165$)	Total biopsies ($n = 4,106$)		Native kidneys ($n = 3,869$)	Total biopsies ($n = 7,442$)		Native kidneys ($n = 7,034$)
	n	%	%[a]	n	%	%[a]	n	%	%[a]
Chronic nephritic syndrome	1,759	52.7	55.4	1,944	47.3	50.0	3,703	49.8	52.5
Nephrotic syndrome	711	21.3	22.4	1,044	25.4	27.0	1,755	23.6	24.9
Rapidly progressive nephritic syndrome	200	6.0	6.3	292	7.1	7.5	492	6.6	7.0
Renal transplantation	160	4.8	–	227	5.5	–	387	5.2	–
Renal disorder with collagen disease or vasculitis	116	3.5	3.7	144	3.5	3.7	260	3.5	3.7
Recurrent or persistent hematuria	97	2.9	3.0	111	2.7	2.9	208	2.8	2.9
Renal disorder with metabolic disease	63	1.9	2.0	61	1.5	1.6	124	1.7	1.8
Acute nephritic syndrome	54	1.6	1.6	58	1.4	1.5	112	1.5	1.6
Hypertensive nephropathy	39	1.2	1.2	54	1.3	1.4	93	1.3	1.3
Acute renal failure	36	1.1	1.1	35	0.9	0.9	71	1.0	1.0
Drug-induced nephropathy	13	0.4	0.4	26	0.6	0.6	39	0.5	0.5
Inherited renal disease	6	0.2	0.2	15	0.4	0.4	21	0.3	0.3
HUS/TTP	–	–	–	3	0.1	0.1	3	0.0	0.0
Others	82	2.5	2.6	92	2.2	2.4	174	2.4	2.5
Total	3,336	100.0	100.0	4,106	100.0	100.0	7,442	100.0	100.0

[a] Patients classified as either "Renal graft" or "Renal transplantation" in other categories were also excluded

In the patients with nephrotic syndrome as classified by the clinical diagnosis, primary glomerular disease other than IgAN was the predominant diagnosis in both 2009 and 2010, followed by diabetic nephropathy, which was the same order as in 2007 and 2008 (Table 9). Among the patients with primary glomerular diseases (except IgA nephropathy) who had nephrotic syndrome, MN was dominant, followed by minor glomerular abnormalities, viz., minimal change nephrotic syndrome (MCNS), focal segmental glomerulosclerosis (FSGS), and membranoproliferative glomerulonephritis (MPGN) (types I and III) in 2009. In 2010, minor glomerular abnormalities were the leading diagnosis, followed by MN, FSGS, and MPGN (types I and III) (Table 10).

Clinical diagnosis of membranous nephropathy, minor glomerular abnormalities, and focal segmental glomerulosclerosis in patients with primary glomerular diseases (except IgA nephropathy) in the J-RBR

A subanalysis of the subjects with a clinical diagnosis of MN, minor glomerular abnormalities, and FSGS who had primary glomerular diseases (except IgA nephropathy) was also performed, since these were the most common forms of such diseases. Nephrotic syndrome was the most common clinical diagnosis in cases with primary MN and

primary minor glomerular abnormalities (MCNS) (Tables 11, 12), whereas chronic nephritic syndrome and nephrotic syndrome were the most common in cases with primary FSGS in 2009 and 2010, respectively (Table 13).

Subanalysis of cases of IgA nephropathy in the J-RBR

The profile, distribution of age ranges, classification of the clinical diagnosis, and the pathological diagnosis of IgAN, the most common glomerulonephritis reported in the J-RBR, were further analyzed (Tables 14, 15, 16, 17, 18, S2, S3). The average age of the overall subjects was in the fourth decade. There were no differences in the proportion of patients based on gender, but the age was significantly higher in males than in females in 2009 (Table 14). In terms of the distribution of age ranges, the peak distribution was in the twenties individually in both genders and in the overall cases in 2009, while it was in the thirties in both genders and overall in 2010, as well as in the combined data from 2009 and 2010 (Table 15). Patients younger than 20 years of age comprised 14.4 % of the cases and those 65 years and over comprised 7.9 % of the cases in the combined data from 2009 and 2010 (Table 15). The majority of the clinical and pathological diagnoses were chronic nephritic syndrome (Table 16) and mesangial proliferative glomerulonephritis (Table 17), respectively,

Table 5 The age distribution of classification of clinical diagnoses in native kidneys in J-RBR 2009 and 2010

Classification	2009			2010			Total		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
Chronic nephritic syndrome	44.4 ± 18.8	41.2 ± 17.8	42.8 ± 18.4	43.5 ± 19.3	41.0 ± 18.2	42.2 ± 18.8	43.9 ± 19.1	41.0 ± 18.0	42.5 ± 18.6
Nephrotic syndrome	52.6 ± 21.6	54.7 ± 21.1	53.5 ± 21.4	49.5 ± 23.4	50.9 ± 22.6	50.1 ± 23.0	50.8 ± 22.7	52.5 ± 22.0	51.5 ± 22.4
Rapidly progressive nephritic syndrome	64.5 ± 13.0	61.2 ± 17.4	63.0 ± 15.1	65.4 ± 11.5	65.3 ± 15.3	65.4 ± 13.3	65.1 ± 12.1	63.6 ± 16.3	64.4 ± 14.1
Renal disorder with collagen disease or vasculitis	48.0 ± 21.5	46.2 ± 20.1	46.7 ± 20.4	54.3 ± 19.5	46.3 ± 19.6	48.7 ± 19.9	51.6 ± 20.5	46.2 ± 19.8	47.8 ± 20.1
Recurrent or persistent hematuria	33.4 ± 17.4	33.8 ± 16.9	33.6 ± 17.0	49.5 ± 19.0	38.0 ± 17.1	42.6 ± 18.6	41.8 ± 19.9	36.1 ± 17.0	38.4 ± 18.4
Renal disorder with metabolic disease	56.9 ± 12.3	57.9 ± 8.9	57.2 ± 11.5	56.8 ± 14.8	54.8 ± 14.1	56.2 ± 14.5	56.9 ± 13.5	56.2 ± 11.9	56.7 ± 13.0
Acute nephritic syndrome	42.8 ± 19.2	36.0 ± 22.5	39.9 ± 20.7	49.6 ± 17.5	46.6 ± 21.1	48.1 ± 19.3	46.1 ± 18.5	42.0 ± 22.1	44.2 ± 20.3
Hypertensive nephropathy	56.2 ± 13.5	51.0 ± 15.3	55.2 ± 13.8	54.5 ± 15.9	54.7 ± 17.0	54.6 ± 16.0	55.3 ± 14.8	53.3 ± 16.1	54.8 ± 15.1
Acute renal failure	56.0 ± 19.3	56.4 ± 26.2	56.1 ± 21.2	55.2 ± 17.6	58.0 ± 20.6	56.0 ± 18.2	55.6 ± 18.3	57.1 ± 23.1	56.0 ± 19.7
Drug-induced nephropathy	53.6 ± 11.9	35.2 ± 21.6	45.1 ± 18.9	47.3 ± 20.0	60.4 ± 17.6	51.5 ± 19.9	49.1 ± 18.0	49.6 ± 22.7	49.3 ± 19.5
Inherited renal disease	25.0 ± 23.8	40.7 ± 24.1	32.8 ± 23.1	15.0 ± 17.1	24.3 ± 25.3	19.3 ± 21.1	17.7 ± 18.5	29.2 ± 24.9	23.2 ± 22.0
HUS/TTP	–	–	–	10, 69	49	42.6 ± 30.0	10, 69	49	42.6 ± 30.0
Others	50.6 ± 18.2	48.4 ± 19.5	49.6 ± 18.7	48.6 ± 20.9	53.3 ± 18.1	50.5 ± 19.8	49.4 ± 19.6	50.9 ± 18.9	50.0 ± 19.2
Total	48.4 ± 20.0	45.5 ± 20.0	47.0 ± 20.1	48.2 ± 21.0	46.0 ± 20.5	47.1 ± 20.8	48.3 ± 20.6	45.8 ± 20.3	47.1 ± 20.5

in 2009 and 2010. The distribution of chronic kidney disease (CKD) stages, degree of proteinuria and clinical parameters in IgAN were analyzed in the combined data from 2009 and 2010 (Tables 18, S2, S3).

With regard to the stages of CKD in patients with IgAN, stage 2 was predominant in the combined data from 2009 and 2010 (Table 18) and in both genders (Tables S2 and S3). The degree of proteinuria in the 24-h urine or spot urine samples increased with the progression of CKD stages in the combined data from 2009 and 2010 (Table 18) and in both genders (Tables S2 and S3). The systolic and diastolic blood pressure also increased with the progression of the CKD stage (Tables 18, S2, S3). Overall, 37.0 % of IgAN cases were being treated with anti-hypertensive agents and 4.6 % had diabetes mellitus (Table 18).

Cases in the J-KDR not reported in the J-RBR

In cases in the J-KDR not reported in the J-RBR, a clinical diagnosis of chronic nephritic syndrome was predominant in 2009, followed by hypertensive nephropathy, and a clinical diagnosis of renal disorder with metabolic disease (diabetic nephropathy) was predominant in 2010, followed by nephrotic syndrome (Table 19). Polycystic kidney disease was detected in 2010 as a result of the secondary research studies performed on the basis of the J-KDR as described in the "Subjects and methods" section.

Secondary and longitudinal research by the J-RBR/J-KDR

Five of the secondary and longitudinal research studies, viz., the JNSCS, J-IDCS, J-IGACS, JRPGN-CS, and JDNCS, were started in 2009, and the J-PKD was started in 2010 in association with the J-RBR/J-KDR.

Discussion and comments

In 2009, the J-KDR started to register clinically-diagnosed cases without renal biopsies, in addition to cases with renal biopsies included in the J-RBR, which had been started in 2007. More than 80 % of the registered cases were in the J-RBR in 2009 and 2010, and thus the detailed data from the J-RBR and the clinical diagnosis alone for the J-KDR are described in this report.

🖄 Springer

Table 6 The frequency of pathological diagnoses as classified by pathogenesis in J-RBR 2009 and 2010

Classification	2009			2010			Total		
	Total biopsies (n = 3,336)		Native kidneys (n = 3,165)	Total biopsies (n = 4,106)		Native kidneys (n = 3,869)	Total biopsies (n = 7,442)		Native kidneys (n = 7,034)
	n	%	%[a]	n	%	%[a]	n	%	%[a]
IgA nephropathy	1,003	30.1	31.6	1,177	28.7	30.4	2,180	29.3	31.0
Primary glomerular disease (except IgA nephropathy)	862	25.8	27.2	1,090	26.5	28.1	1,952	26.2	27.7
Diabetic nephropathy	184	5.5	5.8	192	4.7	5.0	376	5.1	5.3
Renal graft	161	4.8	–	235	5.7	–	396	5.3	–
Lupus nephritis	137	4.1	4.3	220	5.4	5.7	357	4.8	5.1
MPO-ANCA positive nephritis	129	3.9	4.1	191	4.7	4.9	320	4.3	4.5
Hypertensive nephrosclerosis	123	3.7	3.9	157	3.8	4.1	280	3.8	4.0
Purpura nephritis	64	1.9	2.0	108	2.6	2.8	172	2.3	2.4
Amyloid nephropathy	45	1.3	1.4	58	1.4	1.5	103	1.4	1.5
Infection-related nephropathy	27	0.8	0.9	31	0.8	0.8	58	0.8	0.8
Thin basement membrane disease	26	0.8	0.8	39	1.0	1.0	65	0.9	0.9
PR3-ANCA positive nephritis	13	0.4	0.4	11	0.3	0.3	24	0.3	0.3
Alport syndrome	10	0.3	0.3	16	0.4	0.4	26	0.3	0.4
Thrombotic microangiopathy	9	0.3	0.3	8	0.2	0.2	17	0.2	0.2
Anti-GBM antibody-type nephritis	8	0.2	0.3	16	0.4	0.4	24	0.3	0.3
Others	535	16.0	16.7	557	13.6	13.6	1,092	14.7	15.4
Total	3,336	100.0	100.0	4,106	100.0	100.0	7,442	100.0	100.0

MPO myeloperoxidase, *ANCA* anti-neutrophil cytoplasmic antibody, *PR3* proteinase 3, *GBM* glomerular basement membrane

[a] Patients classified as either "Renal graft" or "Renal transplantation" in other categories were also excluded

The rates of primary glomerular disease (except IgAN) combined with that of IgAN in native renal biopsies were 59.3 %, 56.5 %, 58.8 %, and 58.5 % in 2007, 2008, 2009, and 2010 in the J-RBR. A recent report from a single center in Japan gave the rates as 77.8 % and 75.9 % between 1979 and 2008 and between 2004 and 2008, respectively [5]. In the present report for the J-RBR, the peak distribution of age was in the sixties in the combined data for 2009 and 2010. The difference in the rates of primary glomerular disease including IgAN may have been due to the higher mean ages of native biopsy cases in the J-RBR compared to the single center in this period (mean age, 46.7 vs. 40.8 years; age of the peak number, sixties vs. twenties), because the incidence of secondary glomerular disease increases in elderly patients, as reported previously [5].

IgAN is still the most frequently diagnosed disease in native kidney biopsies in Japan (33.0 %, 30.2 %, 31.6 %, and 30.4 % of cases in 2007, 2008, 2009, and 2010 in the J-RBR) [1, 4–6] similar to other Asian countries [7, 8] and some European countries [9, 10]. The peak distribution of age ranges was the twenties in 2009 and thirties in 2010. In patients with IgAN, the majority (68.1 %) of renal biopsies were performed in CKD stages G1 and G2, with median proteinuria less than 1 g per day (Table 18), suggesting that there was a relatively early diagnosis of this biopsy-proven disease.

In the present clinical data, the degree of proteinuria increased with the progression of the CKD stage, and was more than 1 g per day for the median value in patients with CKD stages G4 and G5 (Tables 18, S1, S2). Previously, the best single predictor for renal deterioration was severe proteinuria on urine dipstick testing ($\geq$100 mg/dL), followed by hypoalbuminemia, mild hematuria, serum total protein levels, diastolic blood pressure, and histological grade, in a cohort study with 10 years follow-up from 1995 in Japan, the cohort of which exhibited a younger median age (27.7 years) and a peak distribution of age ranges in the teens [11, 12]. A recent report suggested that IgAN with nephrotic syndrome had a worse renal outcome compared to IgAN with non-nephrotic syndrome unless partial or complete remission was achieved [13]. Further studies are necessary to elucidate the risk factors or predictors for renal deterioration in IgAN in the present era utilizing the J-RBR, possibly as part of a new secondary clinical study.

MN was the most common histopathology in terms of primary glomerular disease other than IgAN in 2007

Table 7 The frequency of pathological diagnoses as classified by histopathology in J-RBR 2009 and 2010

Classification	2009			2010			Total		
	Total biopsies ($n = 3,336$)		Native kidneys ($n = 3,165$)	Total biopsies ($n = 4,106$)		Native kidneys ($n = 3,869$)	Total biopsies ($n = 7,442$)		Native kidneys ($n = 7,034$)
	n	%	%[a]	n	%	%[a]	n	%	%[a]
Mesangial proliferative glomerulonephritis	1,346	40.3	42.5	1,388	33.8	35.8	2,734	36.7	38.8
Membranous nephropathy	333	10.0	10.5	418	10.2	10.8	751	10.1	10.7
Minor glomerular abnormality	293	8.8	9.2	559	13.6	14.4	852	11.4	12.1
Crescentic and necrotizing glomerulonephritis	180	5.4	5.7	262	6.4	6.8	442	5.9	6.3
Focal segmental glomerulosclerosis	167	5.0	5.2	211	5.1	5.4	378	5.1	5.3
Nephrosclerosis	163	4.9	5.2	208	5.1	5.4	371	5.0	5.3
Renal graft	151	4.5	–	227	5.5	–	378	5.1	–
Membranoproliferative glomerulonephritis (types I and III)	85	2.5	2.7	97	2.4	2.5	182	2.4	2.6
Chronic interstitial nephritis	71	2.1	2.1	61	1.5	1.6	132	1.7	1.8
Sclerosing glomerulonephritis	63	1.9	2.0	44	1.1	1.1	107	1.4	1.5
Endocapillary proliferative glomerulonephritis	61	1.8	1.9	67	1.6	1.7	128	1.7	1.8
Acute interstitial nephritis	45	1.3	1.4	62	1.5	1.6	107	1.4	1.5
Acute tubular necrosis	9	0.3	0.3	10	0.2	0.2	19	0.3	0.2
Dense deposit disease	3	0.1	0.1	5	0.1	0.1	8	0.1	0.1
Others	366	11.0	11.3	487	11.9	12.5	853	11.5	12.0
Total	3,336	100.0	100.0	4,106	100.0	100.0	7,442	100.0	100.0

[a] Patients classified as either "Renal graft" or "Renal transplantation" in other categories were also excluded

Table 8 The frequency of pathological diagnoses as classified by histopathology in primary glomerular disease except IgA nephropathy in native kidneys in J-RBR 2009 and 2010

Classification	2009		2010		Total	
	n	%	n	%	n	%
Membranous nephropathy	259	30.1	330	30.3	589	30.2
Minor glomerular abnormalities	216	25.1	408	37.5	624	32.0
Mesangial proliferative glomerulonephritis	167	19.4	86	7.9	253	13.0
Focal segmental glomerulosclerosis	113	13.1	149	13.7	262	13.4
Membranoproliferative glomerulonephritis (types I and III)	48	5.6	51	4.7	99	5.1
Crescentic and necrotizing glomerulonephritis	19	2.2	18	1.7	37	1.9
Endocapillary proliferative glomerulonephritis	8	0.9	24	2.2	32	1.6
Chronic interstitial nephritis	7	0.8	3	0.3	10	0.5
Sclerosing glomerulonephritis	7	0.8	3	0.3	10	0.5
Nephrosclerosis	5	0.6	7	0.6	12	0.6
Acute interstitial nephritis	1	0.1	0	–	1	0.1
Acute tubular necrosis	0	–	1	0.1	1	0.1
Others	11	1.3	9	0.8	20	1.0
Total	861	100.0	1,089	100.0	1,950	100.0

Table 9 The frequency of pathological diagnoses as classified by pathogenesis in nephrotic syndrome in native kidneys in J-RBR 2009 and 2010

Classification	2009		2010		Total	
	n	%	n	%	n	%
Primary glomerular disease (except IgA nephropathy)	442	62.3	696	66.7	1,138	64.9
Diabetic nephropathy	85	12.0	78	7.5	163	9.3
IgA nephropathy	30	4.2	36	3.5	66	3.8
Lupus nephritis	30	4.2	58	5.6	88	5.0
Amyloid nephropathy	27	3.8	41	3.9	68	3.9
Infection-related nephropathy	6	0.8	7	0.7	13	0.7
Hypertensive nephrosclerosis	6	0.8	10	0.9	16	0.9
Purpura nephritis	4	0.6	8	0.8	12	0.7
Alport syndrome	3	0.4	0	–	3	0.2
Thrombotic microangiopathy	1	0.1	1	0.1	2	0.1
PR3-ANCA positive nephritis	1	0.1	0	–	1	0.1
MPO-ANCA positive nephritis	1	0.1	2	0.2	3	0.2
Others	74	10.4	106	10.2	180	10.3
Total	710	100.0	1,043	100.0	1,753	100.0

MPO myeloperoxidase, *ANCA* anti-neutrophil cytoplasmic antibody, *PR3* proteinase 3

Table 10 The frequency of pathological diagnoses as classified by histopathology in primary glomerular disease except IgA nephropathy in nephrotic syndrome in native kidneys in J-RBR 2009 and 2010

Classification	2009		2010		Total	
	n	%	n	%	n	%
Membranous nephropathy	178	40.3	227	32.6	405	35.6
Minor glomerular abnormalities	172	38.9	348	50.0	520	45.7
Focal segmental glomerulosclerosis	47	10.6	82	11.8	129	11.3
Membranoproliferative glomerulonephritis (types I and III)	25	5.7	18	2.6	43	3.8
Mesangial proliferative glomerulonephritis	11	2.5	13	1.9	24	2.1
Crescentic and necrotizing glomerulonephritis	2	0.5	2	0.3	4	0.4
Sclerosing glomerulonephritis	2	0.5	0	–	2	0.2
Endocapillary proliferative glomerulonephritis	1	0.2	5	0.7	6	0.5
Others	4	0.9	1	0.1	5	0.4
Total	442	100.0	696	100.0	1,138	100.0

(31.4 %), 2008 (25.7 %), and 2009 (30.1 %) in the J-RBR and was also the most common type in primary nephrotic syndrome in 2007 (44.0 %) and 2009 (40.3 %) in the J-RBR. MN was also the most common primary cause of nephrotic syndrome in a northern European Caucasian population, with a biopsy rate of 4.5 per million population per year [14]. A total of 68.7 % and 68.8 % of primary MN cases exhibited nephrotic syndrome as the clinical diagnosis at the time of renal biopsy in 2009 and 2010 in the J-RBR. Yokoyama et al. recently reported in their clinical data analysis of 501 cases collected from the combined data of the J-RBR from 2007 to 2010 that nearly half of primary MN (49.1 %) cases showed a daily proteinuria of 3.5 g or higher [15]. The renal survival rate was 60 % at 20 years after diagnosis in patients with primary MN, and the renal survival rate in patients on steroid therapy was

significantly higher in patients on supportive therapy alone in Japan [16], while spontaneous remission was reported to be common (32 %) in patients with primary MN with nephrotic syndrome in Spain [17], even in patients exhibiting chronic renal impairment [18]. Whether treatment with renin–angiotensin blockers or immunoglobulins other than steroids has a favorable effect on the renal prognosis of primary MN should be elucidated in future clinical studies.

The minor glomerular abnormalities in primary nephrotic syndrome, which correspond to MCNS, was the most common histopathology reported in 2008 (44.1 %) and 2010 (50.0 %) in the J-RBR. Since MCNS develops in patients at younger ages [5, 15] while primary MN develops in a relatively elderly population [15, 16], the frequency of these diseases may depend on the distribution of

Table 11 The frequency of clinical diagnoses in membranous nephropathy in primary glomerular disease except IgA nephropathy in native kidneys in J-RBR 2009 and 2010

Classification	2009		2010		Total	
	n	%	n	%	n	%
Nephrotic syndrome	178	68.7	227	68.8	405	68.8
Chronic nephritic syndrome	74	28.6	93	28.2	167	28.4
Recurrent or persistent hematuria	3	1.2	3	0.9	6	1.0
Renal disorder with collagen disease or vasculitis	1	0.4	1	0.3	2	0.3
Hypertensive nephropathy	1	0.4	0	–	1	0.2
Rapidly progressive nephritic syndrome	0	–	1	0.3	1	0.2
Renal disorder with metabolic disease	0	–	1	0.3	1	0.2
Acute nephritic syndrome	0	–	1	0.3	1	0.2
Acute renal failure	0	–	1	0.3	1	0.2
Others	2	0.8	2	0.6	4	0.7
Total	259	100.0	330	100.0	589	100.0

Table 12 The frequency of clinical diagnoses in minor glomerular abnormalities in primary glomerular disease except IgA nephropathy in native kidneys in J-RBR 2009 and 2010

Classification	2009		2010		Total	
	n	%	n	%	n	%
Nephrotic syndrome	172	79.6	348	85.3	520	83.3
Chronic nephritic syndrome	35	16.2	50	12.3	85	13.6
Recurrent or persistent hematuria	5	2.3	5	1.2	10	1.6
Acute renal failure	1	0.5	0	–	1	0.2
Rapidly progressive nephritic syndrome	1	0.5	1	0.2	2	0.3
Acute nephritic syndrome	1	0.5	1	0.2	2	0.3
Hypertensive nephropathy	0	–	1	0.2	1	0.2
Others	1	0.5	2	0.5	3	0.5
Total	216	100.0	408	100.0	624	100.0

the age ranges of patients registered in each year. Indeed, the rate of native biopsies of subjects younger than 20 years of age slightly increased from 11.4 % in 2009 to 12.7 % in 2010 (Table 3) and the mean age of patients with nephrotic syndrome slightly decreased from 53.5 years in 2009 to 50.1 years in 2010 (Table 5) in the J-RBR.

The average age of rapidly progressive nephritic syndrome was the highest (64.4 years) in the age distribution in the classification of clinical diagnosis in the J-RBR (Table 5). Elderly subjects (65 years and over) comprised nearly 25 % of cases, and very elderly subjects (80 years and over) comprised 2.5 % of the cases in the combined data for 2009 and 2010 in the J-RBR. It has been reported that there were statistically significant differences in the renal disease spectrum between elderly and younger subjects [19, 20]. The frequency of rapidly progressive nephritic syndrome in the clinical diagnosis dramatically increased from 4.0 % in the younger group (20–64 years)

to 19.6 % in the very elderly in the combined data from 2007 to November 2011 in the J-RBR [20]. A nationwide survey of rapidly progressive glomerulonephritis (RPGN) was conducted between 1989 and 2007 in Japan, and showed that 64.0 % of patients had pauci-immune-type RPGN, including 42.0 % renal-limited vasculitis, 19.4 % microscopic polyangiitis, and 2.6 % Wegener's granulomatosis (currently granulomatosis with polyangiitis) [21]. Since the frequency of myeloperoxidase–anti-neutrophil cytoplasmic antibody (MPO-ANCA)-positive nephritis has increased recently [22], a further subanalysis of rapidly progressive nephritic syndrome in the J-RBR should be performed to validate the recently published Japanese guidelines for RPGN [23].

Five new secondary research studies of the J-KDR were started in 2009, viz., the J-NSCS, J-IDCS, J-IGACS, J-RPGNCS, and J-DNCS, and the J-PKD was started in 2010. The J-RBR and J-KDR initiated two more clinical

Table 13 The frequency of clinical diagnoses in focal segmental glomerulosclerosis in primary glomerular disease except IgA nephropathy in native kidneys in J-RBR 2009 and 2010

Classification	2009		2010		Total	
	n	%	n	%	n	%
Chronic nephritic syndrome	62	54.9	55	36.9	117	44.7
Nephrotic syndrome	47	41.6	82	55.0	129	49.2
Rapidly progressive nephritic syndrome	1	0.9	1	0.7	2	0.8
Renal disorder with metabolic disease	1	0.9	3	2.0	4	1.5
Recurrent or persistent hematuria	1	0.9	1	0.7	2	0.8
Hypertensive nephropathy	0	–	2	1.3	2	0.8
Acute nephritic syndrome	0	–	1	0.7	1	0.4
Inherited renal disease	0	–	1	0.7	1	0.4
Others	1	0.9	3	2.0	4	1.5
Total	113	100.0	149	100.0	262	100.0

Table 14 The profile of IgA nephropathy in native kidneys in J-RBR 2009 and 2010

IgA nephropathy	2009	2010	Total
Total native kidney biopsies (n)	1,001	1,176	2,177
Average age (years)	38.1 ± 17.2	39.3 ± 17.0	38.7 ± 17.1
Median age (years)	35 (24–52)	38 (26–53)	37 (25–52)
Male, n (%)	498 (49.8 %)[a]	585 (49.7 %)	1,083 (49.7 %)
Average age (years)	39.5 ± 18.2[b]	40.5 ± 18.4[b]	40.0 ± 18.3[b]
Median age (years)	38 (24–55)[b]	39 (25–56)	38 (24–56)[b]
Female, n (%)	503 (50.2 %)[a]	591 (50.3 %)	1,094 (50.3 %)
Average age	36.6 ± 15.9[b]	38.1 ± 15.4[b]	37.5 ± 15.7[b]
Median age	34 (24–49)[b]	37 (26–49)	36 (25–49)[b]

[a] Ratio indicates percentage of each gender in each biopsy category

[b] $P < 0.05$ compared to other gender

Table 15 Distribution of age ranges and gender in IgA nephropathy in J-RBR in 2009 and 2010

Age (years)	2009			2010			Total		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
0–9	11	5	16	12	9	21	23	14	37
10–19	73	68	141	80	55	135	153	123	276
20–29	91	116	207	91	127	218	182	243	425
30–39	87	115	202	113	153	266	200	268	468
40–49	65	81	146	94	106	200	159	187	346
50–59	87	62	149	84	75	159	171	137	308
60–69	62	45	107	82	48	130	144	93	237
70–79	19	9	28	20	18	38	39	27	66
80+	3	2	5	9	0	9	12	2	14
Total	498	503	1,001	585	591	1,176	1,083	1,094	2,177
Under 20 (%)	16.9	14.5	15.7	15.7	10.8	13.3	16.3	12.5	14.4
65 and over (%)	9.4	5.2	7.3	11.5	5.4	8.4	10.5	5.3	7.9